Rosuvastatin Reduces Monocyte Activation in HIV-Infected Patients on ART

In a small, placebo-controlled study, oral rosuvastatin decreased monocyte activation while having no significant effect on T-cell activation.

Effective antiretroviral therapy (ART) provides substantial clinical benefit for HIV-infected individuals, but persistent inflammation and immune activation have been linked to increased risk for non-AIDS conditions such as heart disease and cancer. The SATURN Study was designed to evaluate the effects of rosuvastatin on cardiovascular risk, bone health, and immune activation in HIV-infected patients taking ART. Eligibility criteria included fasting low-density lipoprotein cholesterol level ≤130 mg/dL and an elevated marker of immune activation (either ≥19% of CD8 cells expressing CD38⁺HLA-DR⁺ or a high-sensitivity C-reactive protein level ≥2 mg/L).

Of 202 patients screened, 72 were randomized to oral rosuvastatin (10 mg/day) and 75 to place…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Rosuvastatin Reduces Monocyte Activation in HIV-Infected Patients on ART

Topics

Reviewing Author